A5055401972- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Immune cells in cancer
- Chronic Lymphocytic Leukemia Research
- Biosimilars and Bioanalytical Methods
- T-cell and B-cell Immunology
- Cytokine Signaling Pathways and Interactions
- CRISPR and Genetic Engineering
- Monoclonal and Polyclonal Antibodies Research
- Nanowire Synthesis and Applications
- Silicon Carbide Semiconductor Technologies
- Single-cell and spatial transcriptomics
- Viral Infectious Diseases and Gene Expression in Insects
Ludwig-Maximilians-Universität München
2021-2024
German Center for Lung Research
2023-2024
LMU Klinikum
2023-2024
Center for Integrated Protein Science Munich
2021-2022
München Klinik
2020
Abstract Cancer-specific TCF1 + stem-like CD8 T cells can drive protective anticancer immunity through expansion and effector cell differentiation 1–4 ; however, this response is dysfunctional in tumours. Current cancer immunotherapies 2,5–9 promote responses some but not all patients. This variation points towards currently ill-defined mechanisms that limit cell-mediated immunity. Here we demonstrate tumour-derived prostaglandin E2 (PGE 2 ) restricts the proliferative of within tumours,...
The concept of precision cell therapy targeting tumor-specific mutations is appealing but requires surface-exposed neoepitopes, which a rarity in cancer. B receptors (BCR) mature lymphoid malignancies are exceptional that they harbor tumor-specific-stereotyped sequences the form point drive self-engagement BCR and autologous signaling. Here, we use light chain neoepitope defined by characteristic mutation (IGLV3-21R110) for selective poor-risk subset chronic lymphocytic leukemia (CLL) with...
Abstract Background Chimeric antigen receptor (CAR) T cell therapy has been successfully translated to clinical practice for the treatment of B malignancies. The suppressive microenvironment many malignancies is a bottleneck preventing success CAR cells in broader range tumours. Among others, immunosuppressive metabolite adenosine present high concentrations within tumours and dampens anti-tumour function immune consequently therapeutic response. Methods Here, we impact selective A2 A...
Abstract In multiple myeloma (MM), B cell maturation antigen (BCMA)-directed CAR T cells have emerged as a novel therapy with potential for long-term disease control. Anti-BCMA CD8-based transmembrane (TM) and CD137 (41BB) intracellular costimulatory domain are in routine clinical use. As the construct architecture can differentially impact performance efficacy, optimal construction of BCMA-targeting remains to be elucidated. Here, we hypothesized that varying constituents structure known...
<h3>Background</h3> Chimeric antigen receptor (CAR) T cell therapy has transformed the landscape of hematologic malignancy treatment. However, its successful translation to solid cancer treatment remains challenging, primarily due immunosuppressive tumor microenvironment (TME). Prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) emerged as a pivotal player in TME immunosuppression, whereby impact on function been recognized novel immune checkpoint. This study focuses enhancing CAR efficacy against...
Abstract The concept of precision cell therapy targeting tumor-specific mutations is appealing but requires surface-exposed neoepitopes, which a rarity in cancer. B receptors (BCR) mature lymphoid malignancies are exceptional that they harbor tumor-specific-stereotyped sequences the form point drive self-engagement BCR and autologous signaling. Here, we used light chain neoepitope defined by characteristic mutation (IGLV3-21 R110 ) for selective poor-risk subset chronic lymphocytic leukemia...
<h3>Background</h3> Immunotherapeutic approaches, including immune checkpoint blockade and adoptive T cell therapy (ACT) in the form of tumor-infiltrating lymphocytes (TILs), have had marked success treatment melanoma. Despite these successes, many patients are refractory to or relapse with therapy-resistant disease. To overcome limitations, we propose a controlled ACT approach, where cells armed synthetic agonistic receptors (SARs) that conditionally activated only presence target...
<h3>Background</h3> High expression of CD155 (poliovirus receptor, PVR) is associated with a poor prognosis lung adenocarcinoma (LUAD) and triple-negative breast cancer (TNBC) patients. When overexpressed, this molecule inhibits the antitumor function NK cytotoxic T cells through binding to its inhibitory co-receptors TIGIT CD96, downregulation stimulatory CD226 (DNAM-1). However, exact mechanism overexpression on tumor remains unclear. Here we demonstrate that interleukin-22 (IL-22),...